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Objective: The study objective was to examine the influence of glycaemic control and ethnic variations on the incidence and 
progression of diabetic retinopathy (DR).
Design, subjects and setting: Eight hundred and ninety-two persons with type 1 diabetes mellitus, and 1 998 persons with type 
2 diabetes mellitus, who were enrolled in a private diabetes mellitus management programme in South Africa, participated in 
the study. Survival analyses were conducted to assess the relationship between the risk factors and the incidence of DR and 
referable DR, and the progression of DR.
Outcome measures:  Cumulative incidence of diabetic retinopathy and referable diabetic retinopathy.
Results: The seven-year cumulative incidence of DR and referable DR was 536 and 50 cases per 1 000 persons with type 1 diabetes 
mellitus without DR at baseline, and 351 and 47 cases per 1 000 persons with type 2 diabetes mellitus. The seven-year cumulative 
incidence of referable DR was 332 cases per 1 000 persons with type 1 diabetes mellitus with background DR at baseline, and 360 
cases with type 2 diabetes mellitus, representing a seven- and eightfold increase compared to no DR at baseline. After controlling 
for known risk factors for DR, a high baseline haemoglobin A1c (HbA1c) and non-Caucasian ethnicity were associated with the 
incidence of referable DR in patients with type 1 and type 2 diabetes mellitus.
Conclusion: It was revealed in the first study to report on the incidence and progression of DR in South Africa that a high baseline 
HbA1c, ethnicity, and the presence of background DR increased the risk of the development of referable DR.
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Introduction
In South Africa, diabetic retinopathy (DR) is the fourth leading 
cause of blindness, after cataracts, glaucoma and age-related 
macular degeneration; and visual impairment, after refractive 
errors, cataracts and glaucoma; and the third leading cause of 
severe visual impairment, after refractive errors and cataracts in 
persons aged ≥ 50 years.1
The prevalence rate of DR in South Africa is estimated to be 
between 5% and 10%,2 and has been reported to vary in different 
ethnic groups.3–6 There are no reports of incidence rates in the 
country. Incidence rates reported elsewhere in the world have 
mainly been based on Caucasian populations.7–9 Emerging 
evidence suggests that there are ethnic variations in the 
development of DR.10 However, it remains unclear whether these 
variations represent true differences, or are associated with 
glycaemic control or a genetic predisposition to microvascular 
complications, including DR.
Good control of glycaemia, blood pressure and cholesterol has 
been demonstrated to reduce the risk of of DR progressing, and 
is the cornerstone of good diabetes mellitus care.11 However, a 
rapid improvement in glycaemic control in those with prior 
evidence of DR associated with poor glycaemic control may 
increase the risk of existing retinopathy progressing.12
The aim of this study was to examine the incidence of DR and the 
progression of existing DR within a population undergoing 
screening for DR in a private healthcare setting in Johannesburg, 
South Africa. The effect of glycaemic control and ethnic variations 
on the incidence and progression of DR were examined in 
persons with type 1 and type 2 diabetes mellitus.
Subjects, materials and method
The Centre for Diabetes and Endocrinology is a private, multi-
specialist centre based in Johannesburg, South Africa. Details of 
the diabetes mellitus management programme and DR 
screening protocol of the Centre for Diabetes and Endocrinology 
have been published previously.3,13
The study participants were classified as type 1 or type 2 diabetes 
mellitus patients on clinical assessment, according to the 
American Diabetes Association,14 who had undergone at least 
one subsequent DR screening event after the initial baseline 
assessment.
Screening for DR was conducted on an annual basis with one 45° 
macular digital image captured using a Canon® CR6 -45  NM 
camera without mydriasis, between 2001 and 2010. All retinal 
images were independently reviewed and graded by one of 
three senior retinal graders according to a modified UK standard 
DR grading protocol, used by the Diabetic Retinopathy Screening 
Service for Wales.3 Levels of DR were classified as:
•  No DR: If no lesions were detected.
•  Any DR: When at least 1 microaneurysm and/or a blot 
haemorrhage was detected.
•  Background DR: mild or moderate background DR with or 
without possible maculopathy (M1).
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•  Referable DR: Pre-proliferative DR, proliferative DR, as well as 
exudative maculopathy (M2), were classified as referable DR. RDR 
was the level at which further assessment by an ophthalmologist 
was deemed to be necessary.
The haemoglobin A1c (HbA1c), lipid analyses, serum creatinine 
concentrations and albumin to creatinine ratio were determined 
at baseline. The change in HbA1c was calculated using the HbA1c 
concentration either at the time that the referable DR was first 
identified, or if referable DR did not develop from the last known 
screening event, minus the baseline HbA1c level. Study participants 
were considered to have hypertension if their blood pressure was 
found to be above 140/90  mmHg, taken in the right arm after 
they had been seated for five minutes of rest, and/or if they were 
already receiving antihypertensive therapy.
Statistical analysis
All data was anonymised before statistical analysis was conducted 
using SPSS® version 16. The population characteristics were 
described using means and standard deviations for continuous 
variables, and percentages for categorical variables. The Kaplan-
Meier estimator was used to calculate the cumulative incidence 
rates per 1 000 persons. The results are reported with 95% 
confidence intervals (CIs). The log rank test was used to test for 
equivalence between the survival curves of categorical variables. 
Cox proportional hazards regression was used to assess the 
association of clinical risk factors and the development of referable 
DR with hazard ratios and 95% CI calculated for each category of 
diabetes mellitus. Continuous variables, i.e. the duration of diabetes 
mellitus and age at diagnosis were stratified as duration of diabetes 
mellitus (< 7, 7–15 and > 15 years) for patients with type 1 diabetes 
mellitus, and (< 3, 3–8 and > 8 years) for those with type 2 diabetes 
mellitus; and age at diagnosis of diabetes mellitus (≤  11, 12–20, 
21–32 and ≥ 33 years) for participants with type 1 diabetes mellitus, 
and ≤ 42, 43–50, 51–58 and ≥ 59 years for participants with type 2 
diabetes mellitus. These categories were used to ensure an equal 
distribution among the groups. Associations were considered to be 
significant if the p-value was < 0.050.
Results
Between 2001 and 2010, 5 515 persons with diabetes mellitus (1 
537 type 1 and 3 978 type 2) underwent retinal screening. The 
characteristics of the full population at baseline have been 
reported previously.3 The persons included in this analysis had no 
evidence of DR (2 339, 81%) or pre-existing background DR (551, 
19%) at baseline and after at least one further screening event. Of 
the total population (2 890), 892 (31%) had type 1 diabetes 
mellitus and 1 998 (69%) had type 2 diabetes mellitus. The 
baseline characteristics according to DR status for both type 1 
and type 2 diabetes mellitus on entry are shown in Table 1. There 
was a longer duration of diabetes mellitus in persons with type 1 
diabetes mellitus with pre-existing DR at baseline, and they were 
younger at diagnosis than those without previous DR. A higher 
baseline albumin to creatinine ratio was also reported in those 
with pre-existing DR, and they were more hypertensive than 
those without previous DR. There was also a longer duration of 
diabetes mellitus in persons with pre-existing DR with type 2 
diabetes mellitus, and they were younger at diagnosis than those 
without previous DR. A higher baseline HbA1c level and albumin 
to creatinine ratio were also reported for those with pre-existing 
DR than for those without previous DR.
Incidence and progression of diabetes retinopathy
Thirty-five per cent of persons with type 1 diabetes mellitus without 
previous DR developed any DR, i.e. 32% with background DR, and 
3% with referable DR, during the course of the study (Table 1). Of 
those with referable DR, 0.6% had pre-proliferative DR, 2.0% 
maculopathy, and 0.5% pre-proliferative DR with maculopathy. The 
seven-year cumulative incidence of any DR, background DR and 
referable DR in those without DR at baseline was 536; 511 and 50 
cases per 1 000 persons, respectively (Table 2). Twenty-three per 
cent of those with pre-existing background DR developed referable 
DR. Of those with referable DR, 8% had pre-proliferative DR, 66% 
maculopathy, 14% pre-proliferative DR with maculopathy, 5% 
proliferative DR and 7% proliferative DR with maculopathy. The 
seven-year cumulative incidence of referable DR in those with 
background DR at baseline was 332 cases per 1 000 persons. The 
seven-year cumulative incidence of referable DR in persons with 
type 1 diabetes mellitus was sevenfold higher in persons with pre-
existing background DR than in those with no previous DR.
15.3% of those without previous DR with type 2 diabetes mellitus 
developed any DR, consisting of 13.6% background DR and 1.5% 
referable DR (Table 1). The category of referable DR consisted of 
1.40% with maculopathy, and 0.06% pre-proliferative DR with 
maculopathy. No one developed proliferative DR during the 
study. The seven-year cumulative incidence of any DR, background 
DR and referable DR in those without DR at baseline was 351, 331 
and 47 cases per 1 000 persons (Table 2). 19.9%t of those with 
pre-existing background DR developed referable DR, which 
consisted of 3.0% with pre-proliferative DR, 14.9% maculopathy, 
1.7% pre-proliferative DR with maculopathy, and 0.3% 
proliferative DR. The seven-year cumulative incidence of referable 
DR in those with background DR at baseline was 360 cases per 1 
000 persons. The seven-year cumulative incidence of referable DR 
in persons with type 2 diabetes mellitus was eightfold higher in 
those with pre-existing DR than in those without previous DR.
Glycaemic control
The change in HbA1c over the course of the study period was 
minimal in both persons with type 1 and type 2 diabetes mellitus 
[median of 0.1%, interquartile range (IQR) of −0.8 to 0.9%, and 
median of 0.1% (IQR of −0.6 to 0.8%), respectively]. The crude 
hazard ratio for a change in HbA1c failed to reach significance over 
the course of the study using Cox regression analysis (Table 3). 
The crude hazard ratio for a 1% increase in baseline HbA1c was 
associated with a 1.27 (95% CI: 1.16–1.39) and 1.54 (95% CI: 1.36–
1.74) increased risk of developing referable DR for participants 
with type 1 and type 2 diabetes mellitus, respectively. There was a 
1.44 (95% CI: 1.27–1.62) and a 1.33 (95% CI: 1.15–1.54) increased 
hazard of developing referable DR for patients with type 1 and 
type 2 diabetes mellitus, respectively, following a change in 
HbA1c, DR status on entry and the presence of hypertension for 
every 1% increase in baseline HbA1c, after adjusting for age at 
diagnosis of diabetes mellitus, gender and duration of diabetes 
mellitus.
Ethnicity
The characteristics of Caucasians and non-Caucasians at baseline 
in persons with type 1 and type 2 diabetes mellitus are shown in 
Table 4. Eighty-three per cent of type 1 diabetes mellitus patients 
were Caucasian, and 17% non-Caucasian. A significantly lower 
HbA1c on entry was recorded in Caucasians [mean of 8.4% 
(68  mmol/mol) ± 1.0%] than non-Caucasians [mean of 9.2% 
(77 mmol/mol) ± 2.4%], (p < 0.001). Over the course of the study, 
there was a minimal increase in HbA1c of 0.07% (± 1.6%) in 
Caucasians, and a minimal reduction of 0.40% (± 2.2%) in non-
Caucasians (p 0.013). Seventy-three per cent of type 2 diabetes 
mellitus patients were Caucasian, and 27% were non-Caucasian. A 
significantly lower baseline HbA1c was recorded in Caucasians 
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Table 1: Baseline characteristics of those with at least two clinic visits presenting without diabetic retinopathy, and with background diabetic 
retinopathy
Note: DR: diabetic retinopathy, HbA1c: haemoglobin A1c
*: Numbers are presented as mean (± standard deviation)
Characteristics Type 1 diabetes mellitus Type 2 diabetes mellitus
No DR Background  
DR
p-value No DR Background  
DR
p-value
n (%), 95% confi-
dence interval 637 (66.0), 63.0–68.9 255 (26.4), 23.7–29.3
1 702 (80.9), 
79.2–82.5 296 (14.1), 12.7–15.6
Age (years)* 33.5 (15.2) 37.9 (14.0) < 0.001 56.8 (11.5) 57.6 (10.8) 0.271
Gender 0.438 0.191
Male, (n, %) 344 (54.0) 145 (56.9) 1 136 (66.7) 209 (70.6)
Female (n, %) 293 (46.0) 110 (43.1) 566 (33.3) 87 (29.4)
Ethnicity 0.448 < 0.001
Caucasian (n, %) 521 (81.8) 219 (85.9) 1 271 (74.7) 189 (63.9)
Indigenous African 
(n, %) 51 (8.0) 13 (5.1) 186 (10.9) 43 (14.5)
Indian Asian (n, %) 47 (7.4) 17 (6.7) 192 (11.3) 42 (14.2)
Mixed race (n, %) 16 (2.5) 6 (2.4) 46 (2.7) 20 (6.8)
Duration of diabetes 
mellitus (years)* 10.0 (9.6) 18.22 (9.0) < 0.001 5.2 (5.7) 10.6 (7.6) < 0.001 
Age at diagnosis of 
diabetes mellitus 
(years) * 
23.5 (14.0) 19.7 (11.9) 0.223 51.5 (11.5) 46.9 (12.1) < 0.001
Baseline HbA1c  
percent (n, %)* 8.5 (2.1) 8.7 (1.9) 0.179 7.6 (1.7) 8.1 (1.7) < 0.001
Baseline HbA1c  
(mmol/mol) 69 72 60 65
Total cholesterol 
(mmol/L)* 5.0 (1.0) 5.3 (1.0) 0.005 4.9 (1.1) 4.8 (1.1) 0.170
Albumin to creati-
nine ratio* 1.9 (4.8) 3.8 (7.7) 0.013 3.1 (6.8) 6.5 (16.7) 0.029
Hypertension (n, %) 84 (13.2) 52 (20.4) 0.007 896 (52.6) 175 (59.1) 0.039
Smoking status 
(n, %) 107 (16.8) 46 (18.0) 0.657 229 (13.5) 45 (15.2) 0.420
Other therapies (n, %)
ACE inhibitors 73 (11.5) 40 (15.7) 0.086 687 (40.4) 140 (47.3) 0.025
Aspirin 10 (1.6) 2 (0.8) 0.357 286 (16.8) 42 (14.2) 0.262
Incidence of any DR 
(n, %) 221 (34.8) 260 (15.3)
Incidence of back-
ground DR 201 (31.6) 231 (13.6)
Incidence of or 
progression to 
referable DR
20 (3.1) 58 (22.7) 25 (1.5) 59 (19.9)
Development of referable DR (n, %)
Pre-proliferative 
DR with or without 
maculopathy
4 (20.0) 5 (8.6) 0 9 (15.3)
Maculopathy with 
background DR 13 (65.0) 38 (65.5) 24 (96.0) 44 (74.6)
Pre-proliferative 




3 (15.0) 8 (13.8) 1 (4.0) 5 (8.5)
Proliferative DR 0 3 (5.2) 0 1 (1.7)
Proliferative DR plus 
maculopathy, with 
background DR
0 4 (6.9) 0 0
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(p < 0.001). However, this separation did not occur until after 
three  years of follow-up in type 1 diabetes mellitus patients 
(Figure 1). Using Cox regression, the crude hazard ratio for the 
development of referable DR was increased in non-Caucasians 
when compared to Caucasians at 2.0% (95% CI: 1.19–3.56) vs. 
2.7% (95% CI: 1.75– 4.16) for type 1 and type 2 diabetes mellitus, 
respectively (Table 3). After adjusting for age at diagnosis of 
diabetes mellitus, gender, duration of diabetes mellitus, HbA1c at 
baseline and the change in HbA1c, as well as DR status on entry 
[7.5% (58  mmol/mol) ± 1.5%] than in non-Caucasians [8.0% 
(64 mmol/mol) ± 2.0%], (p < 0.001). There was a minimal increase 
in HbA1c of 0.08% over the course of the study period in Caucasians, 
and a minimal reduction in HbA1c of 0.03% in non-Caucasians. 
However, this difference was not significant (p = 0.244).
Caucasians were less likely to develop referable DR than non-
Caucasians in both type 1 (p = 0.006) and type 2 diabetes mellitus 
Table 2: Annual and cumulative incidence of any diabetic retinopathy, background diabetic retinopathy, referable diabetic retinopathy and 
proliferative diabetic retinopathy in persons with type 1 (top) and type 2 (bottom) diabetes mellitus without diabetic retinopathy (left) at baseline and 
with background diabetic retinopathy at baseline (right)
Note: CI: confidence interval, DR: diabetic retinopathy




Incidence of any DR  
(n = 223)
Incidence of background DR 
(n = 203)
Incidence of referable DR  
(n = 20)

























1 29 29 (28.91–29.09) 28 28 (27.91–28.09) 2 2.0 (1.99–2.01) 28 28 (27.77–28.22)
2 134 163 (162.37–163.63) 124 152 (151.39–152.61) 7 9.0 (8.96–9.03) 72 100 (99.04–100.96)
3 91 254 (252.87–255.13) 88 240 (238.89–241.11) 9 18.0 (17.92–18.08) 51 151 (149.41–152.59)
4 65 319 (317.34–320.66) 59 299 (297.38–300.62) 7 25.0 (24.87–25.13) 68 219 (216.18–221.82)
5 77 396 (393.37–398.63) 73 372 (369.40–374.60) 6 31.0 (30.79–31.21) 21 240 (236.43–243.58)
6 77 473 (468.68–477.32) 73 445 (440.72–449.28) 14 45.0 (44.55–45.45) 27 267 (261.82–272.18)
7 63 536 (518.59–553.41) 66 511 (493.51–528.49) 5 50.0 (48.78–51.23) 65 332 (315.28–348.72)
Type 2  
diabetes 
mellitus
Incidence of any DR  
(n = 261)
Incidence of background DR  
(n = 236)
Incidence of referable DR  
(n = 25)





















1 18 18 (17.98–18.02) 17 17 (16.98–17.02) 1 1.0 (0.99–1.00) 21 21 (20.85–21.15)
2 59 77 (76.88–77.12) 52 69 (68.89–69.11) 4 5.0 (4.99–5.01) 86 107 (105.99–108.01)
3 62 139 (138.71–139.29) 57 126 (125.73–126.27) 6 11.0 (10.98–11.02) 77 184 (181.97–186.03)
4 39 178 (177.47–178.53) 34 160 (159.51–160.49) 2 13.0 (12.96–13.04) 50 234 (230.69–237.31)
5 35 213 (212.06–213.94) 35 195 (194.12–195.88) 4 17.0 (16.92–17.08) 45 279 (273.29–284.71)
6 55 268 (265.89–270.11) 56 251 (248.96–253.04) 20 37.0 (36.69–37.31) 81 360 (344.95–375.05)
7 83 351 (341.29–360.71) 80 331 (321.56–340.44) 10 47.0 (45.56–48.44) 0 360 (284.74–435.26)



















Figure 1: Kaplan-Meier curves for the development of referable diabetes retinopathy in Caucasian and non-Caucasian persons with type 1 (left) and 
type 2 (right) diabetes mellitus
Note: RDR: referable diabetic retinopathy
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 32
Incidence and progression of diabetic retinopathy within a private diabetes mellitus clinic in South Africa 131
Discussion
The seven-year cumulative incidence of referable DR in a diabetes 
mellitus management programme based in Johannesburg, South 
Africa, was similar for persons with type 1 diabetes and type 2 
diabetes mellitus without previous DR at 50 and 47 cases per 1 000 
persons, respectively, and 332 and 360 cases per 1 000 persons, 
respectively, for those with pre-existing background DR. Poor 
glycaemic control on entry into the diabetes mellitus management 
programme was associated with a greater risk of developing referable 
DR in both type 1 and type 2 diabetes mellitus patients. Non-
Caucasians were also at an increased risk of developing referable DR 
compared to Caucasians, even after adjusting for confounders, such 
as glycaemic control. The presence of background DR on entry into 
the programme was the strongest association with the subsequent 
development of referable DR, after adjusting for all other risk factors.
and the presence of hypertension, non-Caucasians with type 1 
diabetes mellitus had a 1.77-fold increased hazard of developing 
referable DR (95% CI: 1.01–3.08), and non-Caucasian type 2 
diabetes mellitus a 2.40-fold increased hazard of developing 
referable DR (95% CI: 1.37–3.54), compared to Caucasians.
Baseline diabetic retinopathy status
The multivariate model contained gender, ethnicity, age at 
diagnosis, duration of diabetes mellitus, baseline and the change 
in HbA1c, DR status at entry and the presence of hypertension. 
After adjusting for all of these confounders, DR status on entry 
was associated with the development of referable DR. There was 
a hazard ratio of 5.56 and 11.94, for those with pre-existing 
background DR, compared to those without DR, for type 1 and 
type 2 diabetes mellitus respectively (Table 3).
Table 3: Cox regression analysis (expressed as hazard ratio (95% CI)) for the development of referable diabetic retinopathy
Note: ACE: angiotensin-converting enzyme, DR: diabetic retinopathy, HbA1c: haemoglobin A1c
*:Each variable is adjusted for all other covariates included in Table 3. For example, gender has been adjusted for ethnicity, duration of diabetes mellitus, age at diagnosis of 
diabetes mellitus, baseline haemoglobin A1c, change in haemoglobin A1c and hypertension. All variables were measured at baseline, except for the change in haemoglobin 
A1c which is the haemoglobin A1c concentration at the time that referable diabetic retinopathy developed, or the last time it was recorded in the study minus the baseline 
haemoglobinA1c value
Referable DR (n = 76) Referable DR (n = 79)
Type 1 diabetes mellitus Crude n Adjusted* Type 2 diabetes mellitus Crude n Adjusted*
Gender Gender
Male 1 472 1 Male 1 1 259 1
Female 1.04 (0.66–1.63) 386 1.11 (0.70–1.75) Female 1.02 (0.64–1.61) 617 0.98 (0.60–1.60)
Ethnicity Ethnicity
Caucasian 1 714 1 Caucasian 1 1 379 1
Non-Caucasian 2.00 (1.19–3.56) 144 1.77 (1.01–3.08) Non-Caucasian 2.70 (1.75–4.16) 497 2.40 (1.37–3.54)
Duration of diabetes mellitus (years) Duration of diabetes mellitus (years)
≤ 7 1 326 1 ≤ 7 1 685 1
8–16 4.18 (1.95–8.98) 299 2.80 (1.22–6.40) 8–16 4.38 (1.96–9.79) 692 3.11 (1.29–7.49)
≥ 17 4.37 (2.00–9.52) 233 3.01 (1.19–7.64) ≥ 17 6.27 (2.80–14.05) 499 2.35 (0.92– 5.97)
Age at diagnosis (years) Age at diagnosis (years)
≤ 11 1 216 1 ≤ 11 1 446 1
12–20 0.64 (0.32–1.28) 209 0.72 (0.35–1.47) 12–20 0.91 (0.55–1.49) 473 1.29 (0.76–2.20)
21–32 1.10 (0.61–1.98) 237 1.56 (0.84–2.92) 21–32 0.34 (0.17–0.67) 452 0.64 (0.30–1.35)
≥ 33 1.11 (0.60–2.06) 196 1.54 (0.78–3.02) ≥ 33 0.33 (0.16–0.67) 505 1.02 (0.44–2.34)
Baseline HbA1c 1.27 (1.16–1.39) 1.44 (1.27–1.62) Baseline HbA1c 1.54 (1.36–1.74) 1.33 (1.15–1.54)
Average HbA1c 1.38 (1.23–1.56) Average HbA1c 1.54 (1.36–1.74)
Change in HbA1c 0.97 (0.84–1.12) 1.18 (1.01–1.62) Change in HbA1c 0.91 (0.81–1.03) 1.06 (0.92–1.23)
DR status at baseline Baseline DR grade
No DR 1 607 1 No DR 1 1 595 1
Background DR 8.07 (4.81–13.55) 251 5.56 (3.15–9.80) Background DR 14.93 (9.34–23.84) 281 11.94 (7.09–20.08)
Total cholesterol (mmol/L) Total cholesterol (mmol/L) 
≤ 5.02 1 ≤ 4.87 1
≥5.03 2.71 (1.31–5.63) ≥ 4.88 0.83 (0.48–1.46)
Albumin to creatinine ratio Albumin to creatinine ratio
≤ 0.90 1 ≤ 1.07 1
≥ 0.91 3.60 (1.73–7.51) ≥ 1.08 1.01 (0.54–1.90)
Hypertension Hypertension
Yes 1 724 1 Yes 1 861 1
No 2.47(1.52– 4.03) 134 1.92 (1.11–3.31) No 0.80 (0.52–1.23) 1 015 0.73 (0.45–1.17)
Smoking status 0.79 (0.42– 1.50) Smoking status 1.51 (0.88–2.60)
ACE inhibitors 1.50 (0.84– 2.67) ACE inhibitors 0.60 (0.38–0.96)
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other putative risk factors, including glycaemic control, which has 
previously been shown in prevalence studies in South Africa.3,23 
There is some evidence that HbA1c may vary independently of 
glycaemia in people of different ethnicities.24–26 However, evidence 
that ethnicity modifies the relative association of HbA1c with the 
prevalence of DR has not been found in recent studies.27,28 Other 
possible explanations include ethnic differences in response to 
chronic glycaemia, as well as factors unrelated to glycaemia, such 
as the erythrocyte turnover or the rate of protein glycation, 
anaemia, haemolytic anaemia, thalassaemia and sickle cell 
anaemia.24 An association between polymorphisms of specific 
genes and DR in different ethnicities, including African populations, 
has also been found in studies. However, the evidence is 
conflicting.29 Therefore, whether the increased risk in incidence of 
referable DR in non-Caucasians is owing to differences in the 
underlying risk factors, or some sort of genetic propensity for DR, 
remains unknown.15
In this study, the seven-year cumulative incidence of referable DR 
was 6.6- and 7.7-fold higher in type 1 and type 2 diabetes mellitus 
patients, respectively, when pre-existing background DR was 
evident at the onset of the study compared to when no previous 
DR was evident. There was a 5.6 and 11.9 increased hazard ratio 
for developing referable DR in type 1 and type 2 diabetes mellitus 
patients, respectively, after controlling for all other putative risk 
factors, when pre-existing background DR was present compared 
to when no previous DR was present. This increased risk in the 
development of referable DR once background DR was present, 
has led to a suggestion that annual screening interval in persons 
without DR can be extended to biennial or even triennial,7,30,31 
with annual screening maintained or reinstituted if and when 
background DR is present.18–20 Our findings would support this 
suggestion for both Caucasians and non-Caucasians.
Clearly, achieving good glycaemic and blood pressure control is 
the first step in reducing the risk of the development and 
progression of DR. Patients of non-Caucasian ancestry appear to 
be at higher risk of developing DR than their Caucasian 
A systematic review identified 61 studies in which the prevalence 
and incidence of DR were reported across 21 countries in the 
African region, with only one reported incidence of DR.15,16 The 
study reported on the six-year incidence and progression of DR in 
Mauritius, based on three field digital images of one eye (the 
right), and without defining the type of diabetes mellitus. They 
reported that the incidence of severe non-proliferative and 
proliferative DR in those without previous DR was 0.4% after 
six years, and progression from mild or moderate non-proliferative 
DR was 15%. Differences between this study and ours in the 
methodologies of photographing the retina (one eye only, versus 
both eyes), the classification of DR, as well as population 
characteristics, may account for the lower incidence rates 
reported in this study.
The seven-year cumulative incidence of any DR in persons with 
type 2 diabetes mellitus without previous DR was reported in two 
previous studies. There have been no similar studies with respect 
to type 1 diabetes mellitus.17,18 The seven-year incidence of any 
DR in persons without previous DR in the present study of 351 
cases per 1 000 persons (35%) was higher than that in a Brazilian 
cohort at 17%,17 but lower than that in the Norwich DR screening 
programme at 50%.18 The incidence rates of referable DR reported 
in this study are very similar to those previously reported in 
populations undergoing systematic screening in the UK.7,19,20
It has been demonstrated in evidence from clinical trials that tight 
control of glycaemia reduced the risk of the incidence and 
progression of DR.19,21,22 However, there was only a minimal 
change in glycaemic control in this study. Therefore, after 
controlling for other putative risk factors, baseline HbA1c was a 
stronger predictor of the development of referable DR than the 
changing HbA1c during the study. Also, there was an increased 
risk of developing referable DR in both type 1 and type 2 diabetes 
mellitus patients for every 1% increase in HbA1c at baseline.
Non-Caucasians were at an increased risk of developing DR (both 
type 1 and type 2 diabetes mellitus patients) when adjusting for 
Table 4: Characteristics of the population with type 1 and type 2 diabetes mellitus by ethnicity
Note: ACE: angiotensin-converting enzyme, HbA1c: haemoglobin A1c
*:Data are presented as mean (± standard deviation)
Characteristics Type 1 diabetes mellitus Type 2 diabetes mellitus
Caucasian Non-Caucasian Caucasian Non-Caucasian
n 740 150 1 460 529
Age (years)* 35.1 (15.4) 33.8 (13.9) 54.5 (10.7) 49.8 (10.6)
Gender (n, %)
Male 407 (55.0) 81 (54.0) 1,003 (68.7) 336 (63.5)
Female 333 (45.0) 69 (46.0) 457 (31.3) 193 (36.5)
Duration of diabetes mellitus (years)* 13.3 (10.5) 8.1 (6.9) 6.1 (6.5) 5.8 (5.8)
Age at diagnosis of diabetes mellitus (years)* 21.7 (13.2) 25.7 (14.3) 53.4 (11.2) 44.0 (10.4)
HbA1c (baseline percentage)* 8.4 (1.9) 9.2 (2.4) 7.5 (1.5) 8.3 (2.1)
HbA1c (baseline, mmol/mol) 57 77 58 67
Total cholesterol (mmol/L)* 5.0 (1.0) 5.3 (1.1) 4.9 (1.1) 4.8 (1.0)
Albumin to creatinine ratio* 2.4 (5.3) 3.6 (8.4) 3.8 (10.1) 3.2 (6.0)
Hypertension (n, %) 112 (15.1) 24 (16.0) 826 (56.6) 241 (45.6)
Smoking status (n, %) 132 (17.8) 21 (14.0) 195 (13.4) 78 (14.7)
Other therapies (n, %)
ACE inhibitors 97 (13.1) 16 (10.7) 656 (44.9) 171 (32.3)
Aspirin 12 (1.6) 0 (0.0) 263 (18.0) 65 (12.3)
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counterparts. This needs to be acknowledged. However, overall, 
good general diabetes mellitus care is required in order to reduce 
or eliminate the incidence of blindness due to diabetes mellitus, a 
goal of the Vision 2020 initiative.11,32
This represents a large longitudinal study of a multi-ethnic 
population undergoing screening for DR in post-apartheid South 
Africa, and is the first study to report on the incidence of DR within 
the region using standardised screening and grading protocols; 
recognised as a gap in the research literature.15 The private 
healthcare setting and the large number of Caucasians, compared 
to the low number of other ethnic groups, were limitations of the 
study. This limits its generalisation to the majority of the population 
who would seek diabetes mellitus care in the public sector.
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